Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lessened its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 58.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,843 shares of the life sciences company's stock after selling 31,242 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Illumina were worth $2,919,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new stake in Illumina during the 3rd quarter worth approximately $772,000. Tidal Investments LLC raised its holdings in Illumina by 38.0% during the third quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company's stock valued at $580,000 after acquiring an additional 1,226 shares during the period. Versant Capital Management Inc boosted its stake in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares during the period. GAMMA Investing LLC grew its position in shares of Illumina by 6.1% during the fourth quarter. GAMMA Investing LLC now owns 3,096 shares of the life sciences company's stock worth $414,000 after purchasing an additional 177 shares in the last quarter. Finally, Everence Capital Management Inc. purchased a new position in Illumina in the 4th quarter worth approximately $414,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ILMN has been the subject of a number of research reports. Royal Bank of Canada lowered their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. Robert W. Baird dropped their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Stephens reiterated an "overweight" rating and set a $156.00 price objective on shares of Illumina in a research report on Tuesday, March 11th. Canaccord Genuity Group dropped their price target on shares of Illumina from $115.00 to $92.00 and set a "hold" rating for the company in a research note on Tuesday, April 29th. Finally, TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and dropped their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Illumina has a consensus rating of "Moderate Buy" and an average price target of $137.55.

Illumina Price Performance

ILMN stock traded up $1.82 during mid-day trading on Wednesday, reaching $76.35. The company's stock had a trading volume of 2,467,306 shares, compared to its average volume of 2,274,015. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company's 50 day moving average is $79.21 and its two-hundred day moving average is $114.45. The stock has a market cap of $12.08 billion, a PE ratio of -9.94, a P/E/G ratio of 1.60 and a beta of 1.35. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.